Scarica l'app Stockscreener
3.68
5.40%
-0.21
Dopo l'orario di chiusura:
3.61
-0.07
-1.90%
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
ACXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
New to The Street Announces Episode 741 Airing Tonight on Bloomberg Television at 6:30 PM EST Featuring Canton Networks, Acme Markets, Virtuix Holdings (VTIX), HPB, Jonas & Redman, Acurx Pharmaceuticals (ACXP), and FreeCast (CAST) - ACCESS Newswire
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
ACXP Forecast, Price Target & Analyst Ratings | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
ACXP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
What is the dividend yield of Acurx Pharmaceuticals IncMarket Growth Report & Daily Stock Momentum Reports - baoquankhu1.vn
Acurx Pharmaceuticals Secures Korean Patent To Strengthen DNA Polymerase IIIC Inhibitor Portfolio - BioPharma APAC
Earnings Report: Is Acurx Pharmaceuticals Inc stock undervalued right now2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn
South Korea grants Acurx patent as it pushes new infection drugs - Stock Titan
Day Trade: Can Acurx Pharmaceuticals Inc disrupt its industryProduct Launch & Low Drawdown Trading Strategies - baoquankhu1.vn
Acurx Pharmaceuticals, Inc.Common Stock (Nasdaq:ACXP) Stock Quote - FinancialContent
Can Acurx Pharmaceuticals (ACXP) climb 226.3% to reach the level Wall Street analysts expect? - msn.com
Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ... By GuruFocus - Investing.com Canada
What's going on with Acurx Pharmaceuticals stock today? - MSN
Why is Acurx Pharmaceuticals stock falling Thursday? - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect? - sharewise.com
Can Acurx Pharmaceuticals (ACXP) Surge by 226.3% to Meet the Target Set by Wall Street Analysts? - Bitget
Can Acurx Pharmaceuticals (ACXP) Rise by 226.3% to Meet the Target Set by Wall Street Experts? - Bitget
Acurx signals launch of pivotal recurrent CDI trial in H2 2026 while strengthening ibezapolstat pipeline - MSN
Is Acurx Pharmaceuticals (ACXP) outperforming other medical stocks this year? - MSN
Acurx Pharmaceuticals Drives Stock Surge with Major Clinical Developments - StocksToTrade
Is Acurx Pharmaceuticals (ACXP) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
What's Going On With Acurx Pharmaceuticals Stock Today? - Sahm
Acurx Pharmaceuticals (ACXP) Gets a Buy from Alliance Global Partners - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), BioLife Solutions (BLFS) - The Globe and Mail
Acurx Pharmaceuticals stock gains over 3% on new rCDI trial launch - Investing.com Canada
Acurx Pharmaceuticals (ACXP) Stock Rockets 218% as Phase 3 CDI Trial Gets Green Light - MEXC
Acurx Pharmaceuticals, Inc. (ACXP) Stock: Reduces Net Loss While Expanding Ibezapolstat Clinical Program - parameter.io
Acurx Pharmaceuticals Reports Full Year and Q4 Results, Provides Business Update - National Today
Acurx Pharmaceuticals (ACXP) Stock Explodes 218% on CDI Clinical Trial Breakthrough - MEXC
Acurx Pharma Stock Dips 9% Amid Market Volatility - timothysykes.com
Acurx Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ACXP: Strong phase II results and new rCDI trial drive momentum amid improved financials - TradingView
Earnings call transcript: Acurx Pharmaceuticals Q4 2025 reveals cash boost and R&D progress - Investing.com
ACXP: Ibezapolstat progresses toward first-in-class status for rCDI, with strong results and new trials - TradingView
Acurx Pharmaceuticals (ACXP) Stock Soars 218% Following Phase 3 CDI Trial Approval - parameter.io
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events - Times Record News
Earnings Scheduled For March 13, 2026 - Benzinga
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):